Healthcare-Exclusive Market Intelligence

Know which healthcare markets to move on —
before your competition.

Analyst-built intelligence platform for pharma, medtech, diagnostics & digital health strategy teams worldwide.

Telehealth$87.8B↑ 24%
Genomics$62.1B↑ 19%
MedTech AI$45.2B↑ 31%
Biopharma$112.4B↑ 11%
Wearables$38.4B↑ 27%
Oncology Dx$29.1B↑ 21%
Cell Therapy$18.7B↑ 34%
Telehealth$87.8B↑ 24%
Genomics$62.1B↑ 19%
MedTech AI$45.2B↑ 31%
Biopharma$112.4B↑ 11%
Wearables$38.4B↑ 27%
Oncology Dx$29.1B↑ 21%
Cell Therapy$18.7B↑ 34%
Get a Free Sample Report See How It Works
10,000+Markets tracked
500+Reports live
4–5 daysCustom delivery
800+Strategy teams
AI in Imaging Digital Therapeutics Pharma Oncology MedTech Devices Remote Monitoring Genomics
Trending Markets · 2024–2032 Live
AI in Medical Imaging
$4.2B → $21.8B 22.4%
Digital Therapeutics
$8.5B → $32.1B 18.7%
Molecular Diagnostics
$11.2B → $28.4B 12.3%
Remote Patient Monitoring
$5.8B → $19.7B 16.6%
CAGR, 2024–2032 ↑ 14.2% avg CAGR
Real-world impact

How Databeta moves decisions
that drive real business outcomes

Revenue won. Costs avoided. Capital deployed wisely. See how teams across every function use our intelligence to act before the market moves.

$180M+ Revenue opportunity identified Avg per strategic pivot case
34% Average cost reduction In acquisition & go-to-market spend
3.2× Faster time-to-decision vs. building research in-house
91% Decision confidence rate Reported by strategy teams post-engagement
VP Corporate Strategy
Global MedTech manufacturer · $2.4B annual revenue
↑ $180M revenue thesis 14 months faster entry Avoided wrong market
The situation
“The board approved Southeast Asia as a priority region for FY25. We had a McKinsey deck from 2021 and some internal assumptions. Before we committed $40M in capex, we needed independent validation on which market was actually ready — and which wasn’t.”
What Databeta showed

Vietnam was 18 months ahead of where the board assumed — and Indonesia had a $340M government tender pipeline nobody had modeled.

Modern diagnostic adoption in Vietnam’s private hospitals was already at 68%, not 30%. Two Western incumbents were under-serving the mid-tier hospital segment — a gap large enough to build a $180M revenue thesis around.

Filed market entry in Vietnam Q1 — 14 months ahead of original timeline. The mid-tier hospital strategy became their $180M FY26 revenue thesis.
SEA Diagnostics · Databeta Intel Snapshot
$340M
Indonesia govt tender pipeline, 3-yr
68%
Vietnam private hospital Dx adoption
Market readiness by country
Vietnam
8.8/10
Indonesia
7.6/10
Philippines
6.1/10
Thailand
5.4/10
Malaysia
4.9/10
2 Western incumbents Mid-tier gap identified Govt tender: Q2 2025 CAGR 14.2%
Head of Global Marketing
Digital Health SaaS platform · Series C · 280-person team
$2.1M new pipeline in 1 quarter 34% CAC reduction Was targeting the wrong segment
The situation
“Our Q3 pipeline review showed CAC had risen 28% year-on-year while deal velocity was flat. The CMO wanted answers before the next board meeting. We were spending the same budget across 200 accounts with no segmentation logic — just firmographic assumptions from two years ago.”
What Databeta showed

The fastest-growing buyer segment had no incumbent vendors — and they weren’t targeting it at all.

Mid-sized regional hospital networks were adopting remote patient monitoring 3× faster than enterprise health systems. Shorter approval cycles, $180K–$320K deal sizes, zero competitor coverage. None of their 200 SDRs had touched this segment.

Pivoted 40% of ad spend in 6 weeks. CAC dropped 34%. Pipeline from the new segment hit $2.1M in one quarter — from zero.
Remote Patient Monitoring · Buyer Shift
−34%
CAC after segment pivot
60%
Shorter approval cycles vs enterprise
YoY adoption growth by buyer segment
Regional networks
+44%
Specialty clinics
+31%
Enterprise health
+14%
Govt hospitals
+9%
Deal size $180K–$320K No incumbent vendors 1,240 target accounts Budget cycle: Q1 & Q3
Investment Director
Healthcare-focused private equity · $1.8B AUM
Deal restructured, capital protected 18–24 months timing risk caught Avoided full deployment error
The situation
“We were 3 weeks from IC approval on a $120M growth equity cheque. The target company’s management deck showed impressive CAGR projections, but the assumptions on reimbursement penetration felt optimistic. We needed a defensible third-party view before we could present to the partnership.”
What Databeta showed

The TAM was real — but the company was 18 months early. Reimbursement at 38% meant mainstream adoption was still 2 years out.

CMS policy changes covering their assay category weren’t expected until 2027. The company’s projections assumed 2025 coverage expansion. The investment team restructured with milestone tranches tied to reimbursement thresholds instead of calendar dates.

Deal restructured with milestone-based tranches. Capital protected from 2-year premature deployment. Better entry price. Deal still closed.
Genomics Diagnostics · Reimbursement Trajectory
38%
Current payer coverage, target assay
2027
Expected CMS coverage expansion
Payer coverage trajectory by year
2024 (actual)
38%
2025
43%
2026
51%
2027 post-CMS
74%
2028
88%
26.8% overall CAGR confirmed Reimbursement lag: 18–24 mo Milestone deal restructured
VP Product
Digital Therapeutics startup · Pre-IPO · Series C funded
$94M Series D closed 44M patients unlocked overnight Avoided 2 dead-end roadmaps
The situation
“We had three product directions on the table and enough engineering capacity to seriously pursue one. The board wanted a decision in 30 days. Our internal team had strong clinical intuition but no structured view of which market had the most favourable regulatory and reimbursement conditions right now.”
What Databeta showed

Type 2 diabetes had 5× more reimbursement runway — and a Medicare decision in 6 months that would unlock 44M patients overnight.

Chronic pain had 14 funded competitors. Oncology required a 36-month FDA pathway. T2D DTx had only 3 cleared products, 62% commercial payer coverage, and almost no competition. The timing was almost perfect.

Full pivot to T2D in week 3. Launched 11 months later — 6 weeks after the Medicare ruling. Series D closed at $94M on a $2.8M ARR ramp in 90 days.
DTx Segment Comparison · Opportunity Score
44M
New patients via Medicare ruling
62%
Commercial payer coverage, T2D DTx
Opportunity score by segment
Type 2 Diabetes
9.2/10
Mental Health
7.1/10
Oncology Support
4.8/10
Chronic Pain
3.1/10
3 cleared products only Medicare ruling: 6 months 14 competitors in chronic pain 36-mo oncology pathway
Global Business Development Director
Healthcare AI imaging platform · $60M ARR
Win rate 11% → 29% Sales cycle 11mo → 4.8mo 162 accounts wasting pipeline
The situation
“Twelve months into a new enterprise motion, our win rate had stalled at 11% and average sales cycles were running 11 months. The CRO brought in a revenue consultant who concluded we were prioritising accounts based on company size, not buying intent. We needed a framework to identify who was actually in market.”
What Databeta showed

Only 38 of 200 accounts were actually in buying mode. The other 162 were wasting pipeline capacity, budget and time.

Databeta identified 3 trigger events — PACS contract renewals, radiology head appointments, JCI accreditation timelines — that predicted purchase intent with high precision. Accounts with 2+ active triggers had a 3× higher win rate and a 5-month sales cycle.

Rebuilt entire outbound around 38 trigger-qualified accounts. Win rate: 11% → 29%. Sales cycle: 11 months → 4.8 months. In two quarters.
AI Imaging Sales · Trigger Score Analysis
29%
Win rate after trigger targeting (was 11%)
4.8mo
Sales cycle, trigger-qualified accounts
Win rate by account trigger score
3+ triggers
43%
2 triggers
29%
1 trigger
14%
No triggers
11%
38 of 200 in buying mode PACS renewal cycles JCI accreditation signals Dept head appointments
See what your sample report looks like Illustrative examples based on real market dynamics in our reports.
Decision readiness

From gut feel to
boardroom conviction

See exactly where you are today — and where a single Databeta report takes you. The gap between vague and decided is smaller than you think.

Select your role to see your journey
Free sample report

See the intelligence your
competitors are already using.

Request a free excerpt from any report in our library. Our analyst team will match you with the most relevant intelligence for your market — delivered within 4 business hours. No pitch. No commitment.

Analyst-matched, not algorithm-matched. A real analyst reads your focus and selects the most relevant excerpt — not an automated system.
Delivered in 4 business hours. Most sample requests are fulfilled the same day — often within the hour.
Your strategy stays confidential. All engagements operate under strict confidentiality. We never discuss client focus areas externally.
No report in our library? Tell us your market and we’ll scope a custom brief — delivered in 4–5 business days.
NDA available on request. Discussing a new market entry, acquisition target, or product strategy? We sign mutual NDAs before any strategic conversation. Your intelligence stays yours.
Request your free sample report
Tell us your focus. We’ll match you with the right intelligence within 4 hours.
By submitting you agree to our Privacy Policy. We never sell your data. NDA available on request.
Talk to an analyst

Your strategy deserves a
conversation, not a catalogue.

Market research isn’t just about buying a report. Sometimes you need 30 minutes with an analyst who has spent years tracking your specific market — to pressure-test an assumption, validate a thesis before your board meeting, or understand what the data actually means for your next move.

A conversation that changed the plan
“We were about to commit $40M in capex to a Southeast Asian market entry. One 30-minute call revealed a regulatory change we’d completely missed — it would have delayed us 18 months. We restructured before spending a single dollar.”
→ VP Corporate Strategy · Global MedTech · $2.4B revenue
Free 30-minute call — no charge, no obligation
NDA signed before any strategic discussion begins
Market entry, M&A, new product, GTM — all covered
Scheduled within 24 hours of your request
Your conversation and strategy stays confidential — always
Book a free call
30-minute analyst
strategy session
Tell us what you’re working on. Our analyst comes prepared with market data, competitive context, and informed questions — not a sales deck.
Healthcare Strategy Analyst
10+ years · Pharma, MedTech & Digital Health
Available today
What can we discuss?
Market entry strategy New product development M&A due diligence Competitive benchmarking Investment thesis validation GTM strategy Regulatory landscape Custom research scoping
Typical response: under 2 hours during business hours
Intelligence platform

A live view of what’s moving
healthcare markets right now

A preview of the intelligence inside every Databeta report — competitive positioning, live market signals, and segment heat maps. Updated continuously by our analyst team.

databeta://intelligence-terminal
LIVE FEED
Competitive Positioning GLP-1 Receptor
Market Signals Real-time
Segment Heat Map CAGR 2024–32
Low
High
Databeta Research Intelligence Terminal · Data updated Q1 2025 · 10,000+ markets tracked
PDF Report
Excel Data
PowerPoint Slides
Custom Delivery 4–5 Days
NDA Protected
Methodology · AI vs Human Intelligence

AI generates. Analysts think.

The difference between a data dump and a decision. Why strategy teams trust human intelligence over AI-generated research.

AI Research
Data sourcing
Pattern-matched from public text
No primary source validation. Market figures algorithmically interpolated — not verified against filings or interviews.
Regulatory reading
Summarises headlines only
Cannot interpret what a CMS ruling means for your specific market entry timeline.
Currency
Frozen at training cutoff
A competitor exit last month is invisible. Stale assumptions ship as confident facts.
Accountability
No name. No responsibility.
No analyst to call when the forecast is wrong. Confidence without accountability.
Human Intelligence
Data sourcing
Primary source verified
Every figure traced to regulatory filings, clinical registries, earnings calls, and direct prescriber interviews.
Regulatory reading
Strategic interpretation
The analyst tells you what the ruling means for your exact timeline — judgment, not a headline summary.
Currency
Updated this quarter
Analysts track these markets daily. No training cutoff. No stale assumptions shipped as facts.
Accountability
Named analyst. Direct line.
Every report has a specialist behind it. When markets move — you call them directly.
Capability
AI Research
Databeta Analyst
Market sizing accuracy
Interpolated — no primary validation
340 primary interviews + filing reviews
Regulatory interpretation
Summarises headlines only
Translates ruling to your timeline
Data currency
Frozen at training cutoff date
Updated quarterly — this year’s data
Accountability
No name, no ownership, no recourse
Named analyst — call them directly

Your strategy is not a prompt. It deserves a human mind.

Recent publications

Latest intelligence from our analyst team

Browse all reports
Pharma · Endocrinology March 2025
GLP-1 Receptor Agonist Market Intelligence Report 2025–2034
$53.5B
Market size 2024
19.9%
CAGR 2024–2034
284
Pages
Lead Analyst · Endocrinology
Updated Q1 2025
View report
PDFExcelPPT
Digital Health · AI February 2025
AI in Medical Imaging Market Size & Forecast 2025–2032
$4.2B
Market size 2024
22.4%
CAGR 2024–2032
218
Pages
Lead Analyst · Digital Health
Updated Q1 2025
View report
PDFExcelPPT
Biotech · Cell Therapy January 2025
Cell Therapy Market Size, Pipeline & Competitive Intelligence 2025–2033
$18.7B
Market size 2024
28.4%
CAGR 2024–2033
196
Pages
Lead Analyst · Biotech
Updated Q4 2024
View report
PDFExcelPPT

Every report is analyst-built, primary-source verified, and updated quarterly. No AI-generated summaries. No recycled secondary data. Intelligence you can stake a board decision on.

Global research network

Intelligence delivered to
decision-makers worldwide

From pharma boardrooms in New York to MedTech headquarters in Singapore — Databeta intelligence is cited where decisions are made.

0
Countries served
0
Reports delivered
0
Strategy teams
0
Continents covered
Trusted by strategy teams worldwide
Novo Nordisk
Roche Diagnostics
Medtronic
AstraZeneca
Johnson & Johnson
Siemens Healthineers
Bain & Company
McKinsey Health
Eli Lilly
Philips Healthcare
Apollo Hospitals
Gulf Medical Group
Novo Nordisk
Roche Diagnostics
Medtronic
AstraZeneca
Johnson & Johnson
Siemens Healthineers
Weekly Market Signal

5 market shifts.
Every Monday. Always free.

Analyst-written healthcare market intelligence delivered to your inbox. Read by 2,400+ strategy teams, investors, and consultants globally.

GLP-1 & Obesity Digital Therapeutics AI in Healthcare MedTech M&A Regulatory shifts
Join 2,400+ decision-makers who read it every Monday morning.

No spam. Unsubscribe any time. NDA available for enterprise subscribers.